Other languages Healios K.K.

Equities

4593

JP3835100003

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-05-09 am EDT			5-day change	1st Jan Change
159 ^JPY	0.00%		+7.43%	-3.64%

Apr. 10	Healios Partners with AND Medical Group; Set to Receive Upfront Payment of 60 Million Yen	MT
Apr. 09	Healios K.K. Enters into Joint Research Agreement with AND Medical Group	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Healios K.K. Enters into Joint Research Agreement with AND Medical Group	Apr. 08
Healios K.K. completed the acquisition of Substantially all assets of Abt Holding Company, Advanced Biotherapeutics, Inc, Athersys, Inc. (OTCPK:ATHX.Q), ReGenesys BVBA and ReGenesys, LLC .	Apr. 02
Japanese Shares Hit Fresh 52-Week Peak Ahead of Inflation Data	Feb. 26
Healios K.K. and ProcellCure Inc. Announce Start of ARDS Clinical Trial in Japan	Feb. 01
Japanese Shares Finish Lower After Key Economic Data	Jan. 18
Healios K.K. and Its Wholly Owned Subsidiary ProcellCure Inc. Announce Submission of ARDS Clinical Trial Notification in Japan	Jan. 17
Healios' Ischemic Stroke Trial Data Published in JAMA Neurology Journal	Jan. 17
Healios K.K. AND Medical Group Enter into A Letter of Intent for A Basic Agreement for Joint Research	Jan. 15
California Institute for Regenerative Medicine Awards $1 Million from the California Institute for Regenerative Medicine for Healios' Hypo-immune UDC	23-10-29
HEALIOS K.K. Conducts the Treasure Study to Investigate the Safety and Efficacy of HLCM051	23-10-10
HEALIO K.K. Provides its Innovative eNK Platform for A Novel Research Study on Metastatic Uveal Melanoma At Thomas Jefferson University in Philadelphia	23-09-13
Healios K.K. Establish Subsidiary to Promote the Development	23-08-14
Healios and Saisei Ventures Enter into a Letter of Intent for eNK Research and Development	23-07-10
Healios Announces Establish Subsidiary for ENK Research and Development	23-07-10
Healios K.K. and Saisei Ventures Enter into A Letter of Intent and Establish Subsidiary for Ards Treatment Development	23-07-06
Healios K.K. Announces Use of 3D Bioreactor-Based Manufacturing Method Produced Product for ARDS	23-07-04
HEALIOS K.K. and Sumitomo Pharma Co. Ltd. Announces Start of Phase 1/2 Study in RPE Tear Using RPE Cells Derived from Allogeneic iPS Cells	23-06-22
Healios K.K. Announces Submission of Clinical Trial Notification for RPE Tail Using RPE Cells Derived from Allogeneic iPS Cells	23-05-24
Japan Shares Remain in Green; KDDI Inks 51 Billion Yen Deal With Nippon Telegraph for Internet Initiative Stake	23-05-19
Healios K.K. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Healios K.K.

Equities

4593

JP3835100003

Other languages

Filters